Literature DB >> 33575089

P4HA1 as an unfavorable prognostic marker promotes cell migration and invasion of glioblastoma via inducing EMT process under hypoxia microenvironment.

Xiaosan Zhu1, Shanshan Liu1, Xueou Yang1, Wenjun Wang1, Wei Shao1, Tianhai Ji1,2.   

Abstract

This study aims to explore the mechanism of glioblastoma multiforme (GBM) in hypoxia through metabolomic and proteomic analysis. We showed that the migration and invasiveness of LN18 cells was significantly enhanced after 24 h of hypoxia treatment. The metabolomic and proteomic profiling were conducted in LN18 cells cultured under hypoxia condition. Correlation analysis between significant differential metabolites and proteins revealed seven proteins and ten metabolites, of which metabolite L-Arg was negatively correlated with P4HA1 protein. Meanwhile, the expression of HIF1α, nNOS and P4HA1 was up-regulated, and the concentration of L-Arg and NO was decreased and increased respectively. Knockdown of HIF1α reduced the expression of nNOS and P4HA1, the concentration of NO and the invasiveness of cells, while increased the concentration of L-Arg. Similar changes on P4HA1 expression, the concentration of L-Arg and NO were observed when the expression of nNOS was disrupted. Lastly, knockdown of P4HA1 impaired the invasion of LN18 and T98G cells, probably through regulating the expression of Vimentin, MMP2, MMP9, Snail and E-cadherin. Consistent trends on both the overexpression of these relevant genes, as well as the concentration of L-Arg and NO were also observed in all our overexpression experiments. Besides, we investigated the relationship between P4HA1 expression and prognosis by MTA, CGGA and TCGA databases. Increased P4HA1 level was correlated poor prognosis with advanced histological grade. In summary, we found that hypoxia promotes the migration and invasion of GBM via the L-Arg/P4HA1 axis which maybe an effective molecular marker or predictor of clinical outcome in GBM patients. AJCR
Copyright © 2021.

Entities:  

Keywords:  Hypoxia; P4HA1; glioblastoma multiforme; invasion; migration; prognosis

Year:  2021        PMID: 33575089      PMCID: PMC7868758     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  7 in total

1.  Comprehensive Analysis of CD163 as a Prognostic Biomarker and Associated with Immune Infiltration in Glioblastoma Multiforme.

Authors:  Hao Li; Di Wang; Bolong Yi; Heng Cai; Zhuo Xi; Xin Lou; Zhen Li
Journal:  Biomed Res Int       Date:  2021-08-05       Impact factor: 3.411

2.  P4HA1, a Prognostic Biomarker that Correlates With Immune Infiltrates in Lung Adenocarcinoma and Pan-Cancer.

Authors:  Qi Zhao; Junfeng Liu
Journal:  Front Cell Dev Biol       Date:  2021-12-13

3.  Integrative Analysis of the lncRNA-Associated ceRNA Regulatory Network Response to Hypoxia in Alveolar Type II Epithelial Cells of Tibetan Pigs.

Authors:  Yanan Yang; Yongqing Li; Haonan Yuan; Xuanbo Liu; Yue Ren; Caixia Gao; Ting Jiao; Yuan Cai; Shengguo Zhao
Journal:  Front Vet Sci       Date:  2022-02-08

4.  P4HA1 Regulates CD31 via COL6A1 in the Transition of Glioblastoma Stem-Like Cells to Tumor Endothelioid Cells.

Authors:  Xiangming Han; Qiyan Wang; Sheng Fang; Jialin Wang; Fusheng Liu; Junwen Zhang; Guishan Jin
Journal:  Front Oncol       Date:  2022-04-13       Impact factor: 5.738

5.  The Role of P4HA1 in Multiple Cancer Types and its Potential as a Target in Renal Cell Carcinoma.

Authors:  Yang Li; Yu-Zheng Ge; Yiguan Qian; Ke Chen; Feng Zhao; Zhiqiang Qin; Liuhua Zhou; Luwei Xu; Zheng Xu; Quanliang Dou; Ruipeng Jia
Journal:  Front Genet       Date:  2022-06-23       Impact factor: 4.772

6.  Constructe a novel 5 hypoxia genes signature for cervical cancer.

Authors:  Yang Yang; Yaling Li; Ruiqun Qi; Lan Zhang
Journal:  Cancer Cell Int       Date:  2021-07-03       Impact factor: 5.722

7.  A Hypoxia Gene-Based Signature to Predict the Survival and Affect the Tumor Immune Microenvironment of Osteosarcoma in Children.

Authors:  Feng Jiang; Xiao-Lin Miao; Xiao-Tian Zhang; Feng Yan; Yan Mao; Chu-Yan Wu; Guo-Ping Zhou
Journal:  J Immunol Res       Date:  2021-07-15       Impact factor: 4.818

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.